Rivka Kreitman

SVP, Head of Global Specialty Regulatory Affairs, Teva Pharmaceuticals, USA

Lecture: The Future is Here: Drug/Software Combination Platforms

In 2018, the number of connected devices will top 11 billion – and that's not including computers and phones! There are over 3.8 billion people (more than 50% of the world population) connected to the internet, and over 5B utilize mobile devices. We will review some examples, and discuss the FDA approach to drug/software combination platforms. As Abraham Lincoln said: “"The Best way to predict the future is to create it”. So, welcome to the future!
With vast pharma experience in drug development, business development and commercialization she will address the fast changing world of technology and innovation- not only in the pharma world but in general.


Rivka is a Global Pharmaceutical Executive, with over 35 years of broad academic and pharma experience. A valued team player and team builder with vast experience in drug development, business development and commercialization. Stellar track record in network building to identify and execute significant acquisitions and partnership deals to enrich the pipeline.

Rivka has been with Teva for 25 years during which she has held a number or roles ranging from BD (sourcing of new projects), running pharmacological studies assessing the mechanism of action of Copaxone (a drug for Multiple Sclerosis), Project leadership, managing the North America IR&D function and the Global Clinical Operation, heading the Global Innovative Research and Development (IR&D), focusing mainly on CNS, Autoimmune and Oncology and Heading Global Strategic Marketing, Biologics, Women’s health, Immunology and Cell therapy.  She was also leading the search for new products and the scientific evaluation of all opportunities.

In her current role, Rivka is responsible for leading the global branded Regulatory  Affairs department in Teva, assuring the smooth development and approval of all Teva’s new products, and maintaining the ones that reached the market in compliance with global health authorities regulations.

Rivka earned her PhD at the Weizmann Institute of Science, Israel (Biochemistry) and postdoctoral work at Princeton University, NJ, US (Molecular Biology). Prior to joining Teva, she worked at Tel-Aviv University, Israel (Department of Physiology and Pharmacology, Sackler School of Medicine).

Rivka is a board member of TL Biopharmaceuticals, a Board member of the Philadelphia-Israel chamber of commerce and a member of its Science and Technology Committee and in the scientific Board of the BrainBoost Innovation Center (Segol School of Neuroscience, Tel-Aviv University).

Rivka is committed to making the biggest difference in forwarding and achieving organizational outcomes.